Scientists flipped a brain switch in mice that erased Alzheimer’s plaques and restored memory, hinting at cheap pills that could outpace million-dollar infusions.
Story Snapshot
- Karolinska Institutet and RIKEN researchers pinpoint SST1 and SST4 receptors as natural plaque-clearing triggers.
- Mice gained boosted neprilysin enzyme, fewer amyloid beta plaques, and sharper memory without side effects.
- Path to affordable small-molecule drugs challenges pricey antibody treatments like lecanemab.
- Preclinical success published February 17, 2026, in Journal of Alzheimer’s Disease.
Receptors Unlock Brain’s Natural Defense
Karolinska Institutet in Sweden and RIKEN Center for Brain Science in Japan identified somatostatin receptors SST1 and SST4. These receptors in the hippocampus regulate neprilysin, the enzyme that clears amyloid beta plaques. Plaques define Alzheimer’s, the top dementia cause. Age and disease drop neprilysin levels, allowing buildup. Researchers stimulated SST1 and SST4 in genetically modified mice and cell cultures. Neprilysin surged, plaques shrank, and memory improved markedly.
Scientists discover Alzheimer’s hidden “death switch” in the brain https://t.co/ZQ7Yz00pDn
— European Journal of Neuroscience (@EJNeuroscience) March 23, 2026
Lead Researcher Drives Discovery
Per Nilsson, docent at Karolinska Institutet’s Department of Neurobiology, Care Sciences and Society, led the team. Nilsson stated their findings strengthen the brain’s amyloid beta defense through receptor stimulation. The international collaboration received funding from Swedish Research Council, Hållsten Research Foundation, Alzheimer’s Foundation, and Leif Lundblad Family initiative. No conflicts of interest emerged. This academic effort positions Karolinska and RIKEN as key players in Alzheimer’s innovation.
Preclinical Results Promise Shift from Antibodies
Experiments used mouse models and cell cultures before the February 17, 2026, publication in Journal of Alzheimer’s Disease. Stimulating SST1 and SST4 targeted G protein-coupled receptors, which drugs hit easily. Results showed no serious side effects. This contrasts with FDA-approved lecanemab and donanemab, which directly remove plaques at high cost and risk. Small molecules could cross the blood-brain barrier for pill-based therapy, slashing expenses.
Facts support Nilsson’s view: mouse memory gains and plaque reduction match neprilysin boosts without antibody drawbacks.
Implications Reshape Alzheimer’s Fight
Short-term, the study validates receptor pathways, speeding small-molecule trials. Long-term, pills could replace antibodies, cutting costs for 50 million patients worldwide. Families and caregivers gain from potential memory recovery. Economic access improves; social quality of life rises. Politically, it spurs brain research funding. This complements precedents like IDOL enzyme tweaks reducing plaques and NAD+ restoring advanced disease in mice.
Broader effects diversify neuroscience pipelines. G protein-coupled targeting expands alongside energy balance fixes and lithium influences. Mouse consistency across studies builds credibility, though human trials remain uncertain.
Sources:
Scientists discover brain switches that clear Alzheimer’s plaques
Brain ‘master switch’ discovery could lead to new neurodegenerative therapies
Alzheimer’s disease could be reversed restoring brain balance, study suggests
Alzheimer’s drug discovery pathway
An Alzheimer’s breakthrough 10 years in the making
New study shows Alzheimer’s disease can be reversed, achieve full neurological recovery
Expanding the Alzheimer’s Treatment Landscape: A 2026 Forecast
Brain neuron death occurs throughout life and increases with age
Scientists find a new way to slow memory loss in Alzheimer’s
